The pneumococcal conjugate vaccine (PCV13 or Prevnar 13®) protects against 13 types of pneumococcal bacteria.
Before the vaccine, there were about 700 cases of meningitis, 13,000 blood infections, and 200 deaths from pneumococcal disease each year among children younger than 5 years old. After the vaccine was introduced, these numbers dropped quickly.
PCV13 is recommended for use in infants and young children. Certain older children may also need a dose of PCV13.
PCV13 is recommended for all adults 65 years or older. One dose of PCV13 is also recommended for adults 19 years or older with conditions that weaken the immune system, such as HIV infection, organ transplantation, leukemia, lymphoma, and severe kidney disease.
Recent Announcements >